The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells

References

• Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, . Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol. 2004;22:1696–705.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8 + NK-T cells in humans and mice. J Clin Immunol. 2002;22:131–6.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49.
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, . Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673–9.
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–96.
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau SK, Liu BH, Ng LH, Yong HX, Hui KM. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology. 2009;126:423–35.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther. 2009;9:831–40.
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Winkler-Pickett RT, Yagita H, Young HA. Comparative studies of CD3– and CD3 + CD56 + cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol. 1991;136: 486–95.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, . Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol. 2008;20:841–8.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8 + T cells. Blood. 2004;103:3065–72.
   PubMed Web of Science ®Google Scholar
• Kuci S, Rettinger E, Voss B, Weber G, Stais M, Kreyenberg H, . Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica. 2010;95:1579–86.
   PubMed Web of Science ®Google Scholar
• Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, . Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol. 2006;34: 1219–29.
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116:78–86.
   PubMed Web of Science ®Google Scholar
• Lefterova P, Schakowski F, Buttgereit P, Scheffold C, Huhn D, Schmidt-Wolf IG. Expansion of CD3 + CD56 + cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy. Haematologica. 2000;85:1108–9.
   Google Scholar
• Marin V, Pizzitola I, Agostoni V, Giordano Attianese GM, Finney H, Lawson A, . Cytokine induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010;95:2144–52.
   PubMed Web of Science ®Google Scholar
• Pievani A, Belussi C, Klein C, Rambaldi A, Golay J, Introna M. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood. 2011;117:510–8.
   PubMed Web of Science ®Google Scholar
• Di Santo JP, Kuhn R, Muller W. Common cytokine receptor gamma chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting. Immunol Rev. 1995; 148:19–34.
   Google Scholar
• Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67–83.
   PubMed Web of Science ®Google Scholar
• Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005; 86:209–39.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Bacon CM, Riedy MC, O'Shea JJ. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol. 1996;60:441–52.
   PubMed Web of Science ®Google Scholar
• Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, . IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16 + and. J Immunother. 2010;33:200–10.
   PubMed Web of Science ®Google Scholar
• Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, . IL-2 regulates FOXP3 expression in human CD4 + CD25 + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571–9.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142–51.
   PubMed Web of Science ®Google Scholar
• Waldmann T. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res. 2002;4(3): S161–7.
   Google Scholar
• Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol. 2002;22:51–6.
   PubMed Web of Science ®Google Scholar
• Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8 + memory T cells by opposing cytokines. Science. 2000;288:675–8.
   PubMed Web of Science ®Google Scholar
• Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der BM, de Jong D, . Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol. 2009;37:376–85.
   PubMed Web of Science ®Google Scholar
• Becker S, Tonn T, Fussel T, Uhrberg M, Bogdanow M, Seifried E, . Assessment of killer cell immunoglobulin-like receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. Hum Immunol. 2003;64:183–93.
   Google Scholar
• Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, . Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–84.
   PubMed Web of Science ®Google Scholar
• Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;2010:435745. Epub 2010 Mar 30.
   PubMed Web of Science ®Google Scholar
• Laurin D, Marin V, Biagi E, Pizzitola I, Agostoni V, Gallot G, . Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells. J Biomed Biotechnol. 2010;2010:234540. Epub 2010 Jun 13.
   Google Scholar
• Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, . Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;8:129.
   PubMed Web of Science ®Google Scholar
• Chen BA, Li M, Sun ZY, Li CP, Gao C, Sun YY, . Effect of dendritic cells co-cultured with cytokine induced killer cells on cytotoxicity against drug resistant K562 cells. Zhonghua Xue Ye Xue Za Zhi. 2005;26:355–8.
   Google Scholar
• Erhardt M, Gorschluter M, Sager J, Ziske C, Strehl J, Lilienfeld-Toal MV, . Transfection of human monocyte-derived dendritic cells with CpG oligonucleotides. Immunol Cell Biol. 2005;83:278–85.
   Google Scholar
• Ozdemir O, Savasan S. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine- activated killer cell cytotoxicity against human leukemia/lymphoma cells. Clin Immunol. 2005;115:240–9.
   PubMedGoogle Scholar
• Wang Y, Zheng X, Wei H, Sun R, Tian Z. Different roles of IL-15 from IL-2 in differentiation and activation of human CD3 + CD56 + NKT-like cells from cord blood in long term culture. Int Immunopharmacol. 2008;8:927–34.
   Google Scholar
• Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, . Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res. 2010;30:3493–9.
   PubMed Web of Science ®Google Scholar
• Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, . The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181:6738–46.
   PubMed Web of Science ®Google Scholar
• Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, . TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 2001;97:2067–74.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Liu LQ, He YL, Kong WJ, Huang SA. Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells. Acta Pharmacol Sin. 2010;31:861–6.
   Google Scholar
• Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, . Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009;37:616–28.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang W, Jiang H, Li H, Cao S, Ren X. CD4 + T cells in CIKs (CD4 + CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radiopharm. 2008;23: 342–54.
   Google Scholar
• Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318–27.
   PubMed Web of Science ®Google Scholar
• Blaser BW, Roychowdhury S, Kim DJ, Schwind NR, Bhatt D, Yuan W, . Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood. 2005;105:894–901.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Cheng PJ, Yan DC, Lee PT, Hsaio HS. Effect of interleukin-15 on alloreactivity in umbilical cord blood. Transpl Immunol. 2006;16:112–6.
   Google Scholar
• Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest. 1998;102:2126–35.
   PubMed Web of Science ®Google Scholar
• Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923–31.
   PubMed Web of Science ®Google Scholar
• Rettinger E, Schumm M, Pfeiffer M, Kuci S, Willasch A, Handgretinger R, . Identification and selective depletion of alloreactive T-cells for adoptive immunotherapy. Lab Hematol. 2010;16:8–22.
   Google Scholar
• Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137:305–10.
   PubMed Web of Science ®Google Scholar
• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, . Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007; 92:952–9.
   PubMed Web of Science ®Google Scholar